Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.
- Revenue in GBP (TTM)2.23bn
- Net income in GBP147.61m
- Incorporated2005
- Employees8.97k
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
- Websitehttps://www.hikma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | 407.08m | -324.12m | 3.75bn | 702.00 | -- | 18.08 | -- | 9.21 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -38.72 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Glenmark Pharmaceuticals Ltd | 1.10bn | -176.17m | 3.77bn | 15.56k | -- | 5.17 | -- | 3.44 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| BridgeBio Pharma Inc | 169.80m | -418.10m | 3.93bn | 550.00 | -- | -- | -- | 23.16 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Avidity Biosciences Inc | 8.44m | -177.63m | 3.97bn | 253.00 | -- | 5.54 | -- | 470.08 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.72bn | 405.04m | 4.00bn | 11.60k | 9.75 | 1.53 | 7.73 | 2.32 | 1,020.54 | 1,020.53 | 4,335.98 | 6,494.05 | 0.5724 | 1.46 | 4.05 | 68,856,070.00 | 13.62 | 11.64 | 15.34 | 13.28 | 67.11 | 58.18 | 23.80 | 18.93 | 3.08 | -- | 0.0153 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
| Siegfried Holding AG | 1.12bn | 98.48m | 4.01bn | 3.93k | 38.51 | 5.12 | 23.54 | 3.59 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Laboratorios Farmaceuticos ROVI SA | 657.12m | 116.26m | 4.03bn | 2.11k | 34.00 | 8.83 | 29.96 | 6.14 | 2.60 | 2.60 | 14.74 | 10.03 | 0.9364 | 0.9838 | 5.34 | 369,045.00 | 16.56 | 18.90 | 22.75 | 25.58 | 58.01 | 59.82 | 17.69 | 20.13 | 0.771 | 812.80 | 0.135 | 34.37 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| Rohto Pharmaceutical Co Ltd | 1.37bn | 156.32m | 4.12bn | 7.26k | 25.52 | 3.20 | 20.33 | 3.01 | 135.21 | 135.21 | 1,183.75 | 1,079.72 | 0.8259 | 2.59 | 4.17 | 37,310,920.00 | 9.57 | 8.54 | 13.02 | 11.79 | 58.07 | 58.59 | 11.59 | 10.30 | 1.93 | -- | 0.0614 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Hikma Pharmaceuticals Plc | 2.23bn | 147.61m | 4.20bn | 8.97k | 28.50 | 2.45 | 14.12 | 1.88 | 0.6642 | 0.6642 | 10.04 | 7.72 | 0.6284 | 1.76 | 3.67 | 249,083.30 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| GlaxoSmithKline Pharmaceuticals Limited | 320.40m | 54.73m | 4.25bn | 3.21k | 77.74 | 25.80 | 69.53 | 13.28 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Financiere de Tubize SA | 0.00 | 155.07m | 4.38bn | -- | 28.23 | 2.75 | 28.23 | -- | 4.13 | 4.13 | 0.00 | 42.45 | 0.00 | -- | -- | -- | 9.64 | 7.04 | 9.85 | 7.24 | -- | -- | -- | 145.70 | -- | -- | 0.0161 | 20.94 | -- | -- | 3.50 | -20.93 | -- | 11.61 |
| Organon & Co | 4.93bn | 813.27m | 4.43bn | 10.00k | 5.44 | 118.28 | 4.42 | 0.8991 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Aspen Pharmacare Holdings Limited | 1.81bn | 206.45m | 4.56bn | 8.61k | 21.99 | 1.25 | 17.15 | 2.52 | 10.96 | 10.96 | 96.12 | 192.69 | 0.3286 | 1.28 | 3.33 | 4,958,198.00 | 3.75 | 3.54 | 4.42 | 4.44 | 45.15 | 48.72 | 11.40 | 11.58 | 1.09 | 6.50 | 0.2967 | 19.47 | 5.45 | 1.22 | -19.42 | -1.44 | 1.00 | 1.66 |
Data as of Jul 26 2024. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX
25.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2023 | 11.56m | 5.21% |
| JPMorgan International Bank Ltd.as of 01 Jul 2024 | 10.75m | 4.84% |
| Capital Research & Management Co. (World Investors)as of 01 Jul 2024 | 7.20m | 3.24% |
| BlackRock Advisors (UK) Ltd.as of 31 Dec 2023 | 6.15m | 2.77% |
| Mawer Investment Management Ltd.as of 31 Dec 2023 | 4.66m | 2.10% |
| The Vanguard Group, Inc.as of 01 Jul 2024 | 4.19m | 1.89% |
| Norges Bank Investment Managementas of 01 Jul 2024 | 3.34m | 1.50% |
| Threadneedle Asset Management Ltd.as of 30 Apr 2024 | 3.12m | 1.41% |
| Polar Capital LLPas of 31 May 2024 | 3.11m | 1.40% |
| Royal London Asset Management Ltd.as of 01 Jul 2024 | 2.96m | 1.33% |
More ▼
Data from 31 Dec 2023 - 01 Jul 2024Source: FactSet Research Systems Inc.
